Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues – A mini-review

Hepatitis C virus clearance is expected in more than 95% of patients treated with direct-acting antivirals (DAAs). However, an extensive debate about the impact of DAAs on the development of hepatocellular carcinoma (HCC) is currently ongoing. This review aimed to explore currently available evidenc...

Descripción completa

Detalles Bibliográficos
Autores principales: El Kassas, Mohamed, Elbaz, Tamer, Salaheldin, Mohamed, Abdelsalam, Lobna, Kaseb, Ahmed, Esmat, Gamal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Mini Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526204/
https://www.ncbi.nlm.nih.gov/pubmed/31193326
http://dx.doi.org/10.1016/j.jare.2019.03.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526204/
https://www.ncbi.nlm.nih.gov/pubmed/31193326
http://dx.doi.org/10.1016/j.jare.2019.03.001

Ejemplares similares